Arkolith/Insider Trading/RNA/Form 4

Boyce Sarah

President and CEO, DirectorAvidity Biosciences, Inc. (RNA) · full profile →Form 4 · filed Sep 5, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.5M
Net Open-Market Flow
-$2.5M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 5, 2025Sell(S)50K$49.95$2.5M306K
Sep 5, 2025Option exercise(M)50K$1.24$62K356K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 5, 2025Option exercise(M)50K—$01.0M

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001599901-25-000175) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML